SEARCH

SEARCH BY CITATION

References

  • 1
    Howlader N,Noone AM,Krapcho M, et al., editors. SEER Cancer Statistics Review 1975–2008; National Cancer Institute. Bethesda, MD. Available at:http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
  • 2
    Smith SM,Le Beau MM,Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003; 102: 4352.
  • 3
    Mailankody S,Pfeiffer RM,Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011; 118: 40864092.
  • 4
    Appelbaum FR,Gundacker H,Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 34813485.
  • 5
    Walter R,Othus M,Borthakur G, et al. Quantitative effect of age in predicting empirically-defined treatment-related mortality and resistance in newly diagnosed AML: Case against age alone as primary determinant of treatment assignment [ASH abstract 2191]. Blood 2010; 116: 21.
  • 6
    Lapidot T,Sirard C,Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645648.
  • 7
    Gentles AJ,Plevritis SK,Majeti R,Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304: 27062715.
  • 8
    Taussig DC,Pearce DJ,Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 40864092.
  • 9
    Sanz MA,Grimwade D,Tallman MS, et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 18751891.
  • 10
    Vardiman JW,Thiele J,Arger DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009: 937951.
  • 11
    Weinkauff R,Estey EH,Starostik P, et al. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 1999; 111: 733740.
  • 12
    Bennett JM,Catovsky D,Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451458.
  • 13
    Estey E,Thall P,Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90: 29692977.
  • 14
    Giles FJ,Shen Y,Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival. Leuk Lymphoma 2001; 42: 6773.
  • 15
    Burnett AK,Milligan D,Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 11141124.
  • 16
    Sekeres MA,Elson P,Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009; 113: 2836.
  • 17
    Walter RB,Gooley TA,Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29: 11901197.
  • 18
    Yanada M,Garcia-Manero G,Borthakur G, et al. Relapse and death during first remission in acute myeloid leukemia. Haematologica 2008; 93: 633634.
  • 19
    Medeiros BC,Othus M,Fang M,Roulston D,Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: The Southwest Oncology Group (SWOG) experience. Blood 2010; 116: 22242228.
  • 20
    de Lima M,Strom SS,Keating M, et al. Implications of potential cure in acute myelogenous leukemia: Development of subsequent cancer and return to work. Blood 1997; 90: 47194724.
  • 21
    Marcucci G,Mrozek K,Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 57055717.
  • 22
    Appelbaum FR,Kopecky KJ,Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006; 135: 165173.
  • 23
    Delaunay J,Vey N,Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 2003; 102: 462469.
  • 24
    Nguyen S,Leblanc T,Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 2002; 99: 35173523.
  • 25
    Slovak ML,Kopecky KJ,Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 40754083.
  • 26
    Breems DA,van Putten WL,de Greef GE,V et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 47914797.
  • 27
    Marcucci G,Haferlach T,Dohner H. Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475486.
  • 28
    Schlenk RF,Dohner K,Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 19091918.
  • 29
    Gale RE,Green C,Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 27762784.
  • 30
    Becker H,Marcucci G,Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 596604.
  • 31
    Paschka P,Marcucci G,Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 39043911.
  • 32
    Ley TJ,Ding L,Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 24242433.
  • 33
    Thol F,Damm F,Lüdeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29: 28892896.
  • 34
    Green CL,Evans CM,Hills RK, et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010; 116: 27792782.
  • 35
    Green CL,Evans CM,Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118: 409412.
  • 36
    Metzeler KH,Maharry K,Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2011; 29: 13731381.
  • 37
    Hou HA,Huang TC,Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010; 115: 52225231.
  • 38
    Gaidzik VI,Schlenk RF,Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: A study of the German-Austrian AML Study Group. Blood 2009; 113: 45054511.
  • 39
    Metzeler KH,Hummel M,Bloomfield CD, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008; 112: 41934201.
  • 40
    Marcucci G,Radmacher MD,Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 19191928.
  • 41
    Garzon R,Volinia S,Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 31833189.
  • 42
    Figueroa ME,Lugthart S,Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 1327.
  • 43
    Bullinger L,Ehrich M,Dohner K, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010; 115: 636642.
  • 44
    Kornblau SM,Tibes R,Qiu YH, et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009; 113: 154164.
  • 45
    Dohner H,Estey EH,Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453474.
  • 46
    Kayser S,Dohner K,Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 21372145.
  • 47
    Walter RB,Othus M,Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment. J Clin Oncol, in press.
  • 48
    Wheatley K,Brookes CL,Howman AJ, et al Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598605.
  • 49
    Malfuson JV,Etienne A,Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008; 93: 18061813.
  • 50
    Krug U,Rollig C,Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 2010; 376: 20002008.
  • 51
    Fernandez HF,Sun Z,Yao X,Litzow et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 12491259.
  • 52
    Lowenberg B,Ossenkoppele GJ,van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 12351248.
  • 53
    Lowenberg B,Pabst T,Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 10271036.
  • 54
    Bloomfield CD,Lawrence D,Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 41734179.
  • 55
    Koreth J,Schlenk R,Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 23492361.
  • 56
    Wheatley K,Gray R. Commentary: Mendelian randomization—An update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004; 33: 1517.
  • 57
    Holowiecki J,Grosicki S,Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004; 18: 989997.
  • 58
    Burnett AK,Russell NH,Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 23892395.
  • 59
    Faderl S,Ravandi F,Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 16381645.
  • 60
    Fenaux P,Mufti GJ,Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562569.
  • 61
    Thomas XG. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML [ASCO abstract 6504]. J Clin Oncol 2011; 29.
  • 62
    Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol 2009; 21 ( Suppl 1): S3S5.
  • 63
    Gyurkocza B,Storb R,Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 28592867.
  • 64
    Mohty M,de Lavallade H,Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: A donor vs no donor comparison. Leukemia 2005; 19: 916920.
  • 65
    Horowitz MM. High-resolution typing for unrelated donor transplantation: How far do we go? Best Pract Res Clin Haematol 2009; 22: 537541.
  • 66
    Basara N,Schulze A,Wedding U,Mohren M,Gerhardt A,Junghanss C, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23: 635640.
  • 67
    Schlenk RF,Dohner K,Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28: 46424648.
  • 68
    Wagner JE. Should double cord blood transplants be the preferred choice when a sibling donor is unavailable? Best Pract Res Clin Haematol 2009; 22: 551555.
  • 69
    Brunstein CG,Fuchs EJ,Carter SL, et al. Alternative donor transplantation: Results of parallel phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood grafts. Blood 2011; 118: 282288.
  • 70
    Mantel N,Byar DB. Evaluation of response time data involving transient states: An illustration using heart-transplantation data. J Am Statist Assoc 1974; 69: 8186.
  • 71
    Gooley TA,Chien JW,Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 20912101.
  • 72
    Martin PJ,Counts GWJr,Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 10111016.
  • 73
    Fang M,Storer B,Estey E, et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011; 118: 14901494.
  • 74
    Pagel JM,Gooley TA,Rajendran J, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009; 114: 54445453.
  • 75
    Warren EH,Fujii N,Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115: 38693878.
  • 76
    de Lima M,Giralt S,Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study. Cancer 2010; 116: 54205431.
  • 77
    Konopleva MY,Jordan CT. Leukemia stem cells and microenvironment: Biology and therapeutic targeting. J Clin Oncol 2011; 29: 591599.
  • 78
    Levis M,Ravandi F,Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 32943301.
  • 79
    Cortes J,Perl A,Smith C, et al. A Phase II Open-Label, AC220 Monotherapy Efficacy (ACE) Study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations: Interim results. The 16th Congress of the European Hematology Association 2011 (abstract London); 2011.
  • 80
    Ravandi F,Cortes JE,Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 18561862.
  • 81
    Serve H,Wagner R,Sauerland C, et al. Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: Results from a randomized, placebo-controlled phase II trial [ASH abstract 333]. Blood 2010; 116.
  • 82
    Levis M. FLT3/ITD AML and the law of unintended consequences. Blood 2011; 117: 69876990.
  • 83
    Kern W,Haferlach C,Haferlach T,Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008; 112: 416.
  • 84
    Cilloni D,Renneville A,Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 2009; 27: 51955201.
  • 85
    Buccisano F,Maurillo L,Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010; 116: 22952303.
  • 86
    Gardin C,Turlure P,Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109: 51295135.
  • 87
    Park JH,Panageas KS,Schymura MJ, et al. A population-based study in Acute Promyelocytic Leukemia (APL) suggests a higher early death rate and lower overall survival than commonly reported in clinical trials: Data from the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry in the United States Between 1992–2007 [ASH abstract 872]. Blood 2010; 116.
  • 88
    Breccia M,Latagliata R,Cannella L, et al. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: Association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 2010; 95: 853854.
  • 89
    Ades L,Raffoux E,Chevret S, et al. Is AraC required in the treatment of standard risk APL? Long term results of a randomized trial (APL 2000) from the French Belgian Swiss APL Group [ASH abstract 13]. Blood 2010; 116.
  • 90
    Estey EH,Hutchinson F. Newly diagnosed acute promyelocytic leukemia: Arsenic moves front and center. J Clin Oncol 2011; 29: 27432746.
  • 91
    Ravandi F,Estey EH,Cortes JE, et al. Phase II study of all-trans-retinoic acid and arsenic trioxide, with or without gemtuzumab ozogamicin, for the front-line therapy of patients with acute promyelocytic leukemia [ASH abstract 1080]. Blood 2010; 116.
  • 92
    Estey EH,Giles FJ,Beran M, et al. Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 42224224.
  • 93
    de Botton S,Sanz MA,Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006; 20: 3541.
  • 94
    Lo-Coco F,Cimino G,Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 19951999.
  • 95
    Estey E,Kornblau S,Pierce S, et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996; 88: 756.
  • 96
    Breems DA,van Putten WL,Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 19691978.
  • 97
    Walter RB,Kantarjian HM,Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010; 28: 17661771.
  • 98
    Blum W,Garzon R,Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 74737478.